We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
+5.57%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$277M
AUM Growth
-$20.9M
Cap. Flow
-$20.6M
Cap. Flow %
-7.41%
Top 10 Hldgs %
84.21%
Holding
28
New
6
Increased
8
Reduced
7
Closed
7

Top Buys

1
EOLS icon
Evolus
EOLS
+$33.9M
2
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$30.3M
3
QDEL icon
QuidelOrtho
QDEL
+$29.8M
4
XFOR icon
X4 Pharmaceuticals
XFOR
+$7.89M
5
SCYX icon
SCYNEXIS
SCYX
+$7.29M

Top Sells

1
AMYT
Amryt Pharma plc American Depositary Shares
AMYT
+$91.5M
2
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$27.4M
3
XERS icon
Xeris Biopharma Holdings
XERS
+$7.99M
4
DVAX
Dynavax Technologies
DVAX
+$4.09M
5
CSTL icon
Castle Biosciences
CSTL
+$4.07M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QDEL icon
1
QuidelOrtho
QDEL
$1.19B
$51.3M 18.51%
619,426
+340,345
+122% +$29.8M
EOLS icon
2
Evolus
EOLS
$377M
$32.8M 11.82%
4,506,197
+3,927,402
+679% +$33.9M
ADMA icon
3
ADMA Biologics
ADMA
$2.02B
$32.4M 11.7%
8,793,321
+1,131,631
+15% +$4.19M
LKFT
4
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
$27.8M 10.01%
682,664
-99,625
-13% -$4.06M
AMLX icon
5
Amylyx Pharmaceuticals
AMLX
$1.97B
$24.2M 8.72%
+1,121,028
New +$30.3M
MXCT icon
6
MaxCyte
MXCT
$133M
$18.2M 6.57%
3,966,916
+1,259,826
+47% +$5.79M
XERS icon
7
Xeris Biopharma Holdings
XERS
$1.52B
$14.4M 5.2%
5,500,228
-3,139,977
-36% -$7.99M
THRD
8
DELISTED
Third Harmonic Bio
THRD
$13.4M 4.85%
2,793,149
-338,846
-11% -$1.61M
ATYR
9
aTyr Pharma
ATYR
$50M
$9.99M 3.61%
4,627,224
-198,498
-4% -$433K
XFOR icon
10
X4 Pharmaceuticals
XFOR
$360M
$8.93M 3.22%
+153,509
New +$7.89M
SCYX icon
11
SCYNEXIS
SCYX
$42.4M
$8.69M 3.14%
368,293
+312,043
+555% +$7.29M
XOMA
12
DELISTED
Xoma
XOMA
$6.6M 2.38%
349,399
+31,303
+10% +$587K
RZLT icon
13
Rezolute
RZLT
$444M
$6.08M 2.19%
3,072,476
-15,173
-0.5% -$31.3K
TELA icon
14
TELA Bio
TELA
$32.7M
$4.89M 1.76%
+482,619
New +$4.94M
URGN icon
15
UroGen Pharma
URGN
$1.96B
$4.64M 1.67%
448,508
-253,027
-36% -$2.79M
XGN icon
16
Exagen
XGN
$106M
$3.04M 1.1%
1,049,352
+12,278
+1% +$34.9K
GMDA
17
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$2.9M 1.04%
+1,500,000
New +$2.58M
AVIR icon
18
Atea Pharmaceuticals
AVIR
$390M
$2.81M 1.01%
752,088
+67,580
+10% +$253K
DCTH icon
19
Delcath Systems
DCTH
$442M
$2.1M 0.76%
+378,787
New +$2.37M
CSTL icon
20
Castle Biosciences
CSTL
$733M
$1.26M 0.46%
91,978
-200,888
-69% -$4.07M
AYTU icon
21
AYTU BioPharma
AYTU
$23.1M
$756K 0.27%
+472,369
New +$927K
CDTX
22
DELISTED
Cidara Therapeutics
CDTX
– –
-50
Closed -$1.27K
DVAX
23
DELISTED
Dynavax Technologies
DVAX
– –
-416,519
Closed -$4.09M
TVTX icon
24
Travere Therapeutics
TVTX
$5.27B
– –
-132,005
Closed -$2.97M
AMYT
25
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
– –
-6,278,085
Closed -$91.5M
1
2

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, Stonepine Capital Management held 28 positions worth $277M, down 7% from $298M the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Stonepine Capital Management withdrew a net $20.6M in Q2 2023, closing 7 positions and reducing 7 holdings. Its most notable exit was Amryt Pharma plc American Depositary Shares, an estimated $91.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, Stonepine Capital Management opened a new position in Amylyx Pharmaceuticals worth $24.2M.

  • Stonepine Capital Management's largest Q2 2023 buy was Amylyx Pharmaceuticals: 1,121,028 shares worth $24.2M.
  • Stonepine Capital Management added most to Evolus in Q2 2023, an estimated $33.9M increase.
  • Stonepine Capital Management's biggest Q2 2023 reduction was Xeris Biopharma Holdings, cutting an estimated $7.99M.
  • Stonepine Capital Management fully exited Amryt Pharma plc American Depositary Shares in Q2 2023, selling an estimated $91.5M.
  • Stonepine Capital Management's ten largest holdings make up 84% of its $277M portfolio in Q2 2023.
  • Stonepine Capital Management opened 6 new positions and closed 7 in Q2 2023.
  • Stonepine Capital Management's portfolio value fell 7% quarter-over-quarter to $277M.

Based on Stonepine Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.